University of Washington, Seattle, 98195-7232, USA.
Ann Intern Med. 2011 Jan 18;154(2):113-7. doi: 10.7326/0003-4819-154-2-201101180-00010.
The reliability and interpretability of results from clinical trials can be substantially reduced by missing data. Frequently used approaches to address these concerns, such as upward adjustments in sample sizes or simplistic methods for handling missing data, including last-observation-carried-forward, complete-case, or worst-case analyses, are usually inadequate. Although rational imputation methods may be useful to treat missingness after it has occurred, these methods depend on untestable assumptions. Thus, the preferred and often only satisfactory approach to addressing missing data is to prevent it. Procedures should be in place to maximize the likelihood that outcome data will be obtained at scheduled times of evaluation for all surviving patients who have not withdrawn consent. To meaningfully reduce missing data, it is important to recognize and address many factors that commonly lead to higher levels of missingness.
临床试验的结果的可靠性和可解释性可能会因为数据缺失而大大降低。为了解决这些问题,经常使用的方法,如增加样本量的向上调整或简单的处理缺失数据的方法,包括末次观察结转、完全案例或最差情况分析,通常是不够的。虽然合理的插补方法可能对处理缺失数据后有用,但这些方法依赖于未经检验的假设。因此,处理缺失数据的首选且通常是唯一令人满意的方法是预防它。应采取措施,尽可能提高所有未退出同意的幸存患者在预定评估时间获得结果数据的可能性。为了有意义地减少缺失数据,重要的是要认识和解决通常导致更高缺失率的许多因素。